Community-Acquired Infections
Recent clinical, regulatory, research and industry developments relating to this disease.
<i>Mycoplasma pneumoniae</i>: not a typical respiratory pathogen.
Genomic insights into the emergence and spread of antimicrobial-resistant bacterial pathogens.
Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.
BTS guidelines for the management of community acquired pneumonia in adults: update 2009.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Treatment Ertapenem SUN is indicated in paediatric patients (3 months to 17 years of age)… (2022)
Approval — Quofenix is indicated for the treatment of the following infections in adults: acute bac… (2019)
Approval — Zinforo is indicated for the treatment of the following infections in neonates, infants,… (2012)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Community-Acquired Infections3
- Bacteria2
- Pneumonia2
- Respiratory Tract Infections2
- Bacteriophages1
- Coinfection1
- Meningitis, Bacterial1
- Methicillin-Resistant Staphylococcus aureus1
Leading journals6
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America2
- JAMA network open2
- American journal of respiratory and critical care medicine1
- Clinical microbiology reviews1
- Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin1
- European heart journal1
Leading researchers8
- Anzueto A2
- Dean NC2
- Kommedal Ø2
- Musher DM2
- Whitney CG2
- Ahl J1
- Alverson B1
- Axler O1
Affiliations (unnormalised)6
- Department of Clinical Science2
- Haukeland University Hospital2
- Aix Marseille University1
- Akershus University Hospital1
- ANMCO Research Center1
- Anthea Hospital1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Community-acquired infections are infections acquired outside a health care facility, in contrast to cross infection or other health care-associated acquisition. The grounding frames this as a broad epidemiologic and clinical category rather than a single disease entity, with literature spanning diagnosis, microbiology, epidemiology, and drug therapy.
Community-acquired infections are caused by infectious organisms acquired in the community rather than in a recent health care setting. The supplied grounding specifically highlights bacterial pathogens in this context, including community-acquired pneumonia, community-acquired bacterial meningitis, and community-acquired infections due to organisms such as Acinetobacter spp. and methicillin-resistant Staphylococcus aureus.
The biological mechanisms depend on the causative pathogen, so the grounding does not support a single unified pathophysiology for all community-acquired infections. For bacterial infections, the literature emphasizes antimicrobial resistance and, for some organisms, virulence features that promote immune evasion and progression to invasive disease or sepsis.
Recent exposure to a health care facility is used to distinguish health care-associated infection from community-acquired infection, so absence of such exposure is part of the classification rather than a risk factor. The supplied grounding does not provide specific host or environmental risk factors for the broader category.
Management is described at the level of diagnosis, site-of-care assessment, and empiric antimicrobial therapy, with adjunctive surgical therapy and prevention discussed for some syndromes such as community-acquired pneumonia. The grounding also supports treatment approaches that account for bacterial drug resistance, but it does not provide specific regimens or drug names for the broad category.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Any infection acquired in the community, that is, contrasted with those acquired in a health care facility (CROSS INFECTION). An infection would be classified as community-acquired if the patient had not recently been in a health care facility or been in contact with someone who had been recently in a health care facility.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.